VAPB

Chr 20AD

VAMP associated protein B and C

Also known as: ALS8, VAMP-B, VAP-B

The protein encoded by this gene is a type IV membrane protein found in plasma and intracellular vesicle membranes. The encoded protein is found as a homodimer and as a heterodimer with VAPA. This protein also can interact with VAMP1 and VAMP2 and may be involved in vesicle trafficking. [provided by RefSeq, Jul 2008]

GeneReviewsOMIMResearchGenerating clinical summary…
MultiplemechanismADLOEUF 0.562 OMIM phenotypes
Clinical SummaryVAPB
🧬
Gene-Disease Validity (ClinGen)
amyotrophic lateral sclerosis type 8 · ADDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Moderately constrained gene (pLI 0.58) — some intolerance to loss-of-function variants.
📋
ClinVar Variants
2 unique Pathogenic / Likely Pathogenic· 234 VUS of 418 total submissions
📖
GeneReview available — VAPB
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Moderate LoF intolerance
LoF Constraint?
0.56LOEUF
pLI 0.581
Z-score 2.56
OE 0.18 (0.070.56)
Moderately constrained

More LoF-intolerant than ~75% of genes

Missense Constraint?
1.25Z-score
OE missense 0.70 (0.590.83)
94 obs / 135.0 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?
LoF OE?0.18 (0.070.56)
00.351.4
Missense OE?0.70 (0.590.83)
00.61.4
Synonymous OE?0.88
01.21.6
LoF obs/exp: 2 / 11.3Missense obs/exp: 94 / 135.0Syn Z: 0.68

This gene — mechanism propensity

DN
0.6455th %ile
GOF
0.5170th %ile
LOF
0.49top 25%

This gene has evidence for multiple mechanisms of pathogenicity (dominant-negative and loss-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to dominant-negative as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

DNprediction above median · 1 literature citation
LOF1 literature citation

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Literature Evidence

DNOne such mutation, P56S, was identified in human VAPB that behaves in a dominant negative manner, sequestering wild type protein into cytoplasmic inclusions.1
LOFA mutant, aggregation-prone, form of VAPB (P56S) is linked to a dominantly inherited form of amyotrophic lateral sclerosis; however, it has been unclear whether its pathogenicity is due to toxic gain of function, to negative dominance, or simply to insufficient levels of the wild-type protein produc2

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

418 submitted variants in ClinVar

Classification Summary

Pathogenic2
VUS234
Likely Benign109
Benign56
Conflicting14
2
Pathogenic
234
VUS
109
Likely Benign
56
Benign
14
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
2
0
0
2
Likely Pathogenic
0
0
0
0
0
VUS
8
130
96
0
234
Likely Benign
0
6
68
35
109
Benign
0
0
53
3
56
Conflicting
14
Total813821738415

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

17 pathogenic / likely-pathogenic (of 22) ClinVar copy-number / structural variants overlap VAPB — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

VAPB · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →